From AI Tools to Thought Partners: Why We Built AURA for Pharma Insights
For all the conversation around artificial intelligence transforming pharma, most teams are still using it like a slightly faster intern.
It summarizes reports. It drafts slides. It pulls out themes from transcripts.
Useful? Absolutely. Transformational? Not even close.
There’s a growing gap between what AI can do and how it’s actually being used, especially in commercial and market insights. And if we’re being honest, this moment feels familiar.
In the early days of the internet, companies built websites that looked like digital brochures: static, informational, and one-directional. Only later did we realize the real power wasn’t in replicating what already existed, but in creating something entirely new: dynamic content, real-time interaction, and continuous learning.
AI in pharma today feels like it’s in that same early phase.
AI has already proven its value, just not everywhere
To be fair, AI has already proven its value in parts of the industry. Drug discovery was the first major breakthrough. Companies like Insilico Medicine and Recursion Pharmaceuticals demonstrated that AI could dramatically accelerate target identification and molecule development. The potential impact is significant. According to a 2023 analysis by McKinsey & Company, generative AI could generate between $60 billion and $110 billion annually in value for the pharmaceutical and medical products industry, with much of that early impact concentrated in R&D and clinical development.
But AI didn’t stay in discovery. It spread.
Today, it’s being used to optimize clinical trial design, improve patient recruitment, and predict outcomes. Deloitte has highlighted how AI-driven approaches can reduce trial timelines and address long-standing inefficiencies. Similarly, research from IQVIA suggests that AI-enabled approaches can reduce clinical trial timelines by as much as 20–30%, particularly through better patient identification and site selection.
It’s also being applied in regulatory workflows, manufacturing, and supply chain planning. And in commercial functions, it’s beginning to shape everything from segmentation to content development to omnichannel engagement.
In other words, AI has become part of the infrastructure.
But in insights and marketing, we’re still in early adoption phase
And yet, when you look specifically at marketing and market insights, the way AI is being used still feels… limited.
Most applications fall into a few familiar categories: summarizing research, drafting content, or helping teams work a bit faster. These are meaningful improvements, but they don’t fundamentally change how decisions are made. They operate at the level of tasks, not thinking.
The real opportunity is to move beyond that—to use AI not just as a tool, but as a thought partner.
That shift, however, requires solving a different problem.
It’s not a technology problem. It’s a knowledge problem.
The real bottleneck: how knowledge is stored and used
Pharma companies are sitting on years—sometimes decades—of valuable research. Qualitative interviews, quantitative studies, advisory boards, patient journey work, message testing, and real-world evidence. Each study is meaningful on its own, but the true value lies in how those insights connect across time, across stakeholders, and across decisions.
The challenge is that most of this knowledge is locked in static formats. Slide decks, transcripts, datasets, and reports live in different places, owned by different teams, often difficult to search and even harder to synthesize. As a result, teams rely on what’s recent, what’s accessible, or what they remember—not because they want to, but because the system makes it difficult to do anything else.
This is where AI has the potential to do something fundamentally different.
Instead of asking AI to summarize a single study, the real shift is being able to ask more complex, decision-oriented questions. For example:
“How has physician perception shifted from pre-data disclosure to post-data disclosure in similar therapies, and where are we likely to see resistance with this product?”
That’s not a question tied to one dataset. It requires synthesis across studies, time, and context—exactly the kind of thinking most teams don’t have easy access to today.
This is the problem AURA was built to solve
At Cadence, we’ve spent years working at the intersection of clinical science and commercial strategy, helping teams understand not just what is happening, but why decisions are made the way they are. One pattern kept showing up: the most valuable insights rarely came from a single study. They came from connecting the dots across multiple pieces of work—sometimes across years.
But there was no easy way to do that consistently.
That realization is what led us to build AURA.
AURA is built on a simple but powerful idea: your research shouldn’t sit in files, it should work for you. Instead of treating each study as a standalone deliverable, AURA turns past and current research into a connected, living system of knowledge that you can interact with in real time. You can ask questions across multiple studies and get a single, synthesized answer. You can identify patterns and shifts that weren’t visible within any one project. You can explore new hypotheses based on what you already know, rather than starting from scratch each time.
This isn’t just about speed.
It’s about fundamentally changing how research is used.
Designed for real-world decision making
One of the biggest limitations of general-purpose AI tools is that they lack context. They can process language, but they don’t inherently understand how decisions are made in a complex, highly regulated environment like pharma. They don’t weigh evidence the way experienced researchers do, and they don’t distinguish between signal and noise in a meaningful way.
AURA was built to address that.
It’s not just trained on data; it’s shaped by how market researchers think. That includes how we interpret qualitative nuance, reconcile conflicting inputs, and connect insights to real-world clinical and commercial decisions. Cadence has always operated at the intersection of scientific rigor and practical application, translating complex clinical realities into actionable strategy. AURA extends that same mindset into an AI-driven environment.
What that means in practice is that AURA doesn’t just retrieve information.
It helps teams reason through it.
Where this is going
We’re still early in this evolution, but the direction is clear. AI in pharma is moving from automation to augmentation, from outputs to insights, from isolated tools to systems that support real decision-making. The organizations that benefit most won’t just be the ones adopting AI. They’ll be the ones that rethink how knowledge flows through their teams—and how insights are actually used.
Because for many teams, the opportunity isn’t to do more research.
It’s to finally use what they already have, fully.
If you’re starting to think about how AI could play a bigger role in your insights and decision-making process, it’s worth seeing what this looks like in practice. AURA was built specifically for that next step.
👉 Explore more or request a demo: https://plaid-ai.com/aura-demo
Sources
- McKinsey & Company, The economic potential of generative AI: The next productivity frontier (2023)
- Deloitte, AI in clinical development insights
- IQVIA, Institute for Human Data Science reports on AI in clinical trials (2023–2024)
